680
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Oral sophocarpine protects rat heart against pressure overload-induced cardiac fibrosis

, , , &
Pages 1045-1051 | Received 17 Apr 2013, Accepted 16 Dec 2013, Published online: 12 Mar 2014

Figures & data

Figure 1. Structural formula of sophocarpine.

Figure 1. Structural formula of sophocarpine.

Table 1. Effects of sophocarpine on hemodynamics and cardiac coefficient.

Figure 2. Effects of sophocarpine on the levels of plasma pro-inflammatory cytokines. Values are expressed as the mean ± SD, n = 9–11 animals. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; *p < 0.05 and **p < 0.01 compared with the model group.

Figure 2. Effects of sophocarpine on the levels of plasma pro-inflammatory cytokines. Values are expressed as the mean ± SD, n = 9–11 animals. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; *p < 0.05 and **p < 0.01 compared with the model group.

Figure 3. Effects of sophocarpine on collagen content level. Values are expressed as the mean ± SD, n = 9–11 animals. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; *p < 0.05 and **p < 0.01 compared with the model group.

Figure 3. Effects of sophocarpine on collagen content level. Values are expressed as the mean ± SD, n = 9–11 animals. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; *p < 0.05 and **p < 0.01 compared with the model group.

Figure 4. Effect of sophocarpine on cardiac fibrosis (Masson’s trichrome staining, × 200): (A) sham-operated rats (n = 9), (B) model rats (n = 11), (C) rats treated with sophocarpine 10 mg/kg (n = 9), (D) rats treated with sophocarpine 20 mg/kg (n = 9), and (E) rats treated with sophocarpine 40 mg/kg (n = 10).

Figure 4. Effect of sophocarpine on cardiac fibrosis (Masson’s trichrome staining, × 200): (A) sham-operated rats (n = 9), (B) model rats (n = 11), (C) rats treated with sophocarpine 10 mg/kg (n = 9), (D) rats treated with sophocarpine 20 mg/kg (n = 9), and (E) rats treated with sophocarpine 40 mg/kg (n = 10).

Figure 5. Effects of sophocarpine on MMP-2 and MMP-9 contents. Values are expressed as the mean ± SD, n = 9–11 animals. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; *p < 0.05 and **p < 0.01 compared with the model group.

Figure 5. Effects of sophocarpine on MMP-2 and MMP-9 contents. Values are expressed as the mean ± SD, n = 9–11 animals. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; *p < 0.05 and **p < 0.01 compared with the model group.

Figure 6. Effects of sophocarpine on p-IKBα expression. Western blot analysis of p-IKBα expression. Values are reported as the mean ± SD. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; **p < 0.01 compared with the model group.

Figure 6. Effects of sophocarpine on p-IKBα expression. Western blot analysis of p-IKBα expression. Values are reported as the mean ± SD. Significance was determined by ANOVA followed by Tukey’s test. ##p < 0.01 compared with the sham group; **p < 0.01 compared with the model group.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.